PharmaEssentia USA Corp is a biopharmaceutical company based in Burlington, MA, specializing in the development and innovation of treatments for rare hematological diseases. With a focus on research and development, the company aims to expand and diversify its pipeline of medicines globally, while also engaging in critical markets. Led by a team of experienced professionals, including Chief Scientific Officer Lih-Ling Lin and VP of Corporate Communications and Advocacy Rachel Lipsitz, PharmaEssentia is committed to advancing the field of immunology and inflammation research through the discovery of clinical candidates.
Under the leadership of SVP of Clinical Development and Medical Affairs Raymond Urbanski and General Counsel Sulin Shah, PharmaEssentia strives to provide effective and safe treatments for patients with immune-mediated diseases. With a strong emphasis on scientific expertise and clinical research, the company has published numerous papers and patents in the field of immunology. Additionally, SVP of People Anjana Pursnani brings over 25 years of experience in business and organizational development, ensuring a strong focus on talent management and organizational effectiveness within the company.
Generated from the website